To include your compound in the COVID-19 Resource Center, submit it here.

Private ambition

Why BB Biotech joined mRNA company Moderna’s $500M series G

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before the mRNA company taps the public

Read the full 410 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE